Loading
Life sciences · Review
Pathogens · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection remains a major public health concern globally and in the Philippines. The country continues to face a high burden of TB, multidrug- and rifampicin-resistant TB (MDR/RR-TB), HIV, and HIV-associated TB. Since HIV increases the risk of TB and TB worsens HIV outcomes, co-infection hinders progress toward the End TB Strategy and the UNAIDS 95-95-95 targets. This review summarizes the current knowledge on the epidemiology, prevention, and treatment of TB–HIV co-infection with a focus on the Philippine setting. Key challenges include socioeconomic barriers to care and rising drug resistance. In addition, the lack of an integrated TB–HIV data system disrupts continuity of care and weakens surveillance. Closing these gaps requires a coordinated national response that integrates effective policy with active community engagement. Research-driven and locally adapted strategies will be essential to bring the Philippines closer to its elimination goals.